A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(6 sites)

United States

AdventHealth Orlando, Orlando, Florida

NEXT Oncology, Irving, Texas

France

Centre Leon Berard, Lyon

Gustave Roussy, Villejuif

South Korea

Severance Hospital Yonsei University Health System, Seoul

Samsung Medical Center, Seoul